Myriad Genetics

"'I was leaving my mammogram and I said, 'Oh yeah, my dad's BRCA1 positive.' And the radiologist's whole face changed," she recalls. "I got really nervous, but I was playing it off.'" Tohn's doctor made sure she had the genetic testing done right then before leaving her appointment, and a few weeks later, in June 2025, she received her results." Read more from People: https://lnkd.in/gBGrsU3F Learn more: https://lnkd.in/g4j3_56U #myrisk #partners #genetictesting

"For Jackie Tohn, the last few years have been a rollercoaster. The 'Nobody Wants This' star has been on a career high. But she's also been going through a challenging personal health journey behind the scenes. Now, she's sharing her story publicly in the hopes that others learn about their own genetic risk factors for breast cancer." Read more from Today: https://lnkd.in/gSTegnfP Learn more: https://lnkd.in/g4j3_56U #genetictesting #partners #myrisk

Myriad Genetics joins forces with Nobody Wants This actress Jackie Tohn to raise awareness about the importance of hereditary cancer testing with the MyRisk® Hereditary Cancer Test. Read more: https://lnkd.in/gAAy2-BN #partners #myrisk

Don’t miss the chance to get a preview of the upcoming 𝐏𝐫𝐨𝐥𝐚𝐫𝐢𝐬®+𝐀𝐈 𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐞 𝐂𝐚𝐧𝐜𝐞𝐫 𝐏𝐫𝐨𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐓𝐞𝐬𝐭! Be among the first to see how this enhancement supports deeper insights to help guide active surveillance decisions and personalized treatment planning. Join us for a dynamic dinner exploring the utility of Prolaris+AI: • Topic: Prolaris+AI: The Next Era of Integrated Prostate Cancer Prognostics • Date & Time: Saturday, May 16, 2026 | 6:00 PM – 9:00 PM ET • Location: RPM Italian – Mount Vernon Square • Guest Speakers: Stephen Freedland, MD & Kirk Wojno, MD Seats are limited. Reserve your seat today: https://brnw.ch/21x2wu3 While at #AUA26, visit us at Booth 3511 to meet with our experts to review clinical data and workflow solutions for the Prolaris® Prostate Cancer Prognostic Test, MyRisk® Hereditary Cancer Test, and Precise Tumor® Molecular Profile Test. #ProstateCancer #GeneticInsights #Urology

For patients like Michelle, diagnosed with stage IIA colon adenocarcinoma, germline testing at diagnosis provided clinically actionable context beyond her tumor. Using the MyRisk® Hereditary Cancer Test with STAT priority option (<7 days TAT), her care team identified a pathogenic PTEN variant (Cowden syndrome), which is associated with elevated risks for multiple cancers. This result prompted a genetics referral, guided a coordinated long‑term multi‑organ surveillance plan (including thyroid, breast/endometrial, renal, and colon), and enabled cascade testing for at‑risk relatives. See how comprehensive and timely hereditary results can guide care — before and after surgery. Learn more: https://brnw.ch/21x2uLa #GenomicTesting #CancerCareContinuum #HereditaryCancer #GeneticInsights #STAT

We're heading to World Clinical Biomarkers & Companion Diagnostics Summit Japan and kicking things off with a pre-conference Engager focused on one of the most impactful frontiers in precision oncology: ultra-sensitive, tumor-informed MRD testing. 📍Hyatt Regency Tokyo | May 18 - 20, 2026 🧬Pre-Conference Engager | Monday, May 18, 4 PM JST 𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐢𝐧𝐠 𝐌𝐲𝐫𝐢𝐚𝐝'𝐬 𝐔𝐥𝐭𝐫𝐚-𝐒𝐞𝐧𝐬𝐢𝐭𝐢𝐯𝐞 𝐓𝐮𝐦𝐨𝐫-𝐈𝐧𝐟𝐨𝐫𝐦𝐞𝐝 𝐌𝐑𝐃 𝐀𝐬𝐬𝐚𝐲 Join this deep-dive session to explore how tumor-informed MRD testing is being applied in real clinical and therapeutic development settings, and how MRD insights are shaping patient management, trial design, and drug development decisions today. Our Engager and plenary sessions will feature insights from: 🔹Dr. BORA LIM, Section Chief & Translational Research Director, MD Anderson 🔹Dr. Pavlos Msaouel, MD, PhD, Associate Professor of Genitourinary Medical Oncology, MD Anderson 🔹Dale Muzzey, Chief Scientific Officer, Myriad Genetics 🔹Louis Welebob, Senior Vice President, Companion Diagnostics, Myriad Genetics Whether you're advancing biomarker-driven trials or planning next-generation CDx strategies, this session delivers practical perspectives you can apply across your programs. 👉 Register your interest to attend: https://cdx-japan.com/ #WorldCBDxJapan #MRD #precisiononcology #companiondiagnostics #biomarkers #liquidbiopsy #clinical development

False-negative #cysticfibrosis results can undermine clinical confidence and delay meaningful follow-up. When other prenatal screens rely on only screening for limited variants, certain CFTR pathogenic variants may go unrecognized. The FirstGene® Multiple Prenatal Screen uses advanced AMPLIFY® technology and analytical modeling to deliver up to 99.9% detection of CFTR variants.* Explore how the AMPLIFY® difference can improve CF detection: https://lnkd.in/gNUaQxzb #cfscreening #prenatalscreening #genomics #mfm #obgyn *Wang, J. S., Battey, C. J., Trettin, K., Patel, R., Srinivasan, A., Saikumar, J., Kushnoor, D., Habermeyer, B. F., Ganesh, S., Xu, N., et al. (2026). Simultaneous prenatal cfDNA screening of aneuploidy, recessive single-gene conditions, and fetomaternal blood compatibility. Clinical Chemistry. Advance online publication.

🎉 That's a wrap on #ACOG2026! We had an incredible time in D.C., unveiling the FirstGene® Multiple Prenatal Screen and connecting with so many of you to discuss the future of genetic insight-driven care. Through in-depth conversations and our Claw Machine Challenge, we shared how solutions like the FirstGene® screen are designed to reduce complexity and bring greater clarity to prenatal screening. #teamMyriad

We're proud to contribute to the latest research advancing cancer care and to present new data on the Precise MRD™ Test at this year's #ASCO26 Annual Meeting: The Place to Behold the Future of Cancer Care. These abstracts highlight the role of the Precise MRD™ Test across multiple cancer types, underscoring Myriad's leadership in developing evidence that supports more precise and personalized molecular residual disease (MRD) testing. Attend one of the sessions below or visit Myriad at booth # 25081 to learn how our expanding portfolio of advanced genetic, tumor genomic, and molecular residual disease testing solutions helps empower clinicians with the clarity needed to improve patient outcomes and advance the future of precision oncology. Learn more or request a dedicated meeting: https://brnw.ch/21x2or2 #oncology #myriadoncology #geneticinsights

Are you attending #ASCRS26? Join us today at 12:05 PM ET in Embassy Suites by Hilton Tampa Downtown Convention Center, Gandy Meeting Room for an engaging Lunch Symposium! Unrecognized Risk: How Hereditary Cancer Genetic Testing Can Transform Surgical Planning and Long‑Term Management This educational session will explore how routine pre-operative hereditary cancer genetic testing with the MyRisk® Hereditary Cancer Test can sharpen surgical planning and elevate long-term patient management in colorectal cancer. 𝐅𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐒𝐩𝐞𝐚𝐤𝐞𝐫𝐬: • Paul Johnson, MD, FACS, FASCRS, Methodist Cancer Institute • Vitaliy Poylin, MD, FACS, FASCRS, Northwestern Medicine Digestive Health Center 𝐓𝐨𝐩𝐢𝐜𝐬 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: • Case studies demonstrating the clinical impact of hereditary cancer genetic testing • Practical workflows utilizing Myriad’s suite of services • Real-world implementation of the MyRisk Test at a leading cancer center 𝐒𝐩𝐚𝐜𝐞 𝐢𝐬 𝐥𝐢𝐦𝐢𝐭𝐞𝐝, 𝐫𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐧𝐨𝐰! https://lnkd.in/gCSbDcbw #ColorectalCancer #HereditaryCancer #PrecisionMedicine